Novavax’s updated COVID-19 vaccine receives EUA in Taiwan

Novavax announced that the Taiwan Food and Drug Administration has granted emergency use authorization, EUA, for Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals aged 12 and older. Doses of Novavax’s updated vaccine will be delivered to Taiwan under an existing advanced purchase agreement and will be widely available at vaccination centers across Taiwan. “We are working closely with Taiwan’s authorities to ensure doses of our updated protein-based non-mRNA COVID-19 vaccine are made available at vaccination centers across Taiwan as soon as possible,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “As we head into the holiday season with more time spent together and indoors, COVID-19 infection rates are likely to rise and our best line of defense is vaccination.” Authorization was based on non-clinical data showing that Novavax’s updated COVID-19 vaccine induced functional immune responses for XBB.1.5, XBB.1.16 and XBB.2.3 variants.